193 related articles for article (PubMed ID: 10037250)
1. Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopamine agonists?
Turner HE; Adams CB; Wass JA
Eur J Endocrinol; 1999 Jan; 140(1):43-7. PubMed ID: 10037250
[TBL] [Abstract][Full Text] [Related]
2. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
[TBL] [Abstract][Full Text] [Related]
3. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
5. Prolactin Secreting Pituitary Microadenoma: Results of Transsphenoidal Surgery After Medical Therapy With Dopamine Agonist.
Fraioli MF; Umana G; Pagano A; Fraioli B; Lunardi P
J Craniofac Surg; 2017 Jun; 28(4):992-994. PubMed ID: 28277481
[TBL] [Abstract][Full Text] [Related]
6. The use of surgery for the treatment of prolactinomas.
van't Verlaat JW
Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():34-7. PubMed ID: 8103958
[TBL] [Abstract][Full Text] [Related]
7. Endoscopic Transnasal Approach for Microprolactinomas with Experience of 105 Cases in a Single Center: Paradigmal Shift for Conventional Medical Therapy.
Uzuner A; Yilmaz E; Caklili M; Selek A; Aydemir F; Cabuk B; Anik I; Ceylan S
World Neurosurg; 2023 Feb; 170():e858-e867. PubMed ID: 36481446
[TBL] [Abstract][Full Text] [Related]
8. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
[TBL] [Abstract][Full Text] [Related]
9. Low recurrence rate after partial hypophysectomy for prolactinoma: the predictive value of dynamic prolactin function tests.
Webster J; Page MD; Bevan JS; Richards SH; Douglas-Jones AG; Scanlon MF
Clin Endocrinol (Oxf); 1992 Jan; 36(1):35-44. PubMed ID: 1559298
[TBL] [Abstract][Full Text] [Related]
10. The neurosurgical management of prolactinomas.
Gökalp HZ; Deda H; Attar A; Uğur HC; Arasil E; Egemen N
J Neurosurg Sci; 2000 Sep; 44(3):128-32. PubMed ID: 11126446
[TBL] [Abstract][Full Text] [Related]
11. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Hamilton DK; Vance ML; Boulos PT; Laws ER
Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
[TBL] [Abstract][Full Text] [Related]
12. Relapse of hyperprolactinemia after transsphenoidal surgery for microprolactinoma: lessons from long-term follow-up.
Thomson JA; Gray CE; Teasdale GM
Neurosurgery; 2002 Jan; 50(1):36-9; discussion 39-40. PubMed ID: 11844232
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Endoscopic Transsphenoidal Resection for Prolactinoma: A Retrospective Multicenter Case-series.
Zandbergen IM; Huntoon KM; White TG; Bakker LEH; Verstegen MJT; Ghalib LM; van Furth WR; Pelsma ICM; Dehdashti AR; Biermasz NR; Prevedello DM
Arch Med Res; 2023 Dec; 54(8):102919. PubMed ID: 38040527
[TBL] [Abstract][Full Text] [Related]
14. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
[TBL] [Abstract][Full Text] [Related]
15. Pituitary surgery as alternative to dopamine agonists treatment for microprolactinomas: a cohort study.
Baussart B; Villa C; Jouinot A; Raffin-Sanson ML; Foubert L; Cazabat L; Bernier M; Bonnet F; Dohan A; Bertherat J; Assié G; Gaillard S
Eur J Endocrinol; 2021 Oct; 185(6):783-791. PubMed ID: 34605772
[TBL] [Abstract][Full Text] [Related]
16. Long-term evolution and outcomes of microprolactinoma with medical treatment.
Martín de Santa-Olalla y Llanes M; Andía Melero VM; Jara Albarrán A
Endocrinol Nutr; 2013 Nov; 60(9):489-94. PubMed ID: 23834767
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and surgical outcome of prolactinoma in patients under 14 years old.
Zhao Y; Jin D; Lian W; Xing B; Feng M; Liu X; Wang R
Medicine (Baltimore); 2019 Feb; 98(6):e14380. PubMed ID: 30732174
[TBL] [Abstract][Full Text] [Related]
18. Latent prolactinoma on MRI-selective venous sampling and trans-sphenoidal microsurgical treatment.
Nakagawa H; Iwatsuki K; Yamada M; Hagiwara Y; Moriuchi S; Kadota T
Neurol Res; 2001 Oct; 23(7):691-6. PubMed ID: 11680507
[TBL] [Abstract][Full Text] [Related]
19. Potential for long-term remission of microprolactinoma after withdrawal of dopamine-agonist therapy.
Bronstein MD
Nat Clin Pract Endocrinol Metab; 2006 Mar; 2(3):130-1. PubMed ID: 16932269
[No Abstract] [Full Text] [Related]
20. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
